RESEARCH ARTICLE

Robust, independent and relevant prognostic \( ^{18} \)F-fluorodeoxyglucose positron emission tomography radiomics features in non-small cell lung cancer: Are there any?

Tom Konert\(^\text{1,2} \), Sarah Everitt\(^\text{3,4} \), Matthew D. La Fontaine\(^\text{2} \), Jeroen B. van de Kamer\(^\text{2} \), Michael P. MacManus\(^\text{3,4} \), Wouter V. Vogel\(^\text{1,2} \), Jason Callahan\(^\text{3} \), Jan-Jakob Sonke\(^*\)\(^\text{2} \)

\(^1\)Nuclear Medicine Department, Netherlands Cancer Institute, Amsterdam, The Netherlands, \(^2\)Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands, \(^3\)Division of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia, \(^4\)Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia

\(^*\)j.sonke@nki.nl

Abstract

In locally advanced lung cancer, established baseline clinical variables show limited prognostic accuracy and \( ^{18} \)F-fluorodeoxyglucose positron emission tomography (FDG PET) radiomics features may increase accuracy for optimal treatment selection. Their robustness and added value relative to current clinical factors are unknown. Hence, we identify robust and independent PET radiomics features that may have complementary value in predicting survival endpoints. A 4D PET dataset (\( n = 70 \)) was used for assessing the repeatability (Bland-Altman analysis) and independence of PET radiomics features (Spearman rank: \(|\rho|<0.5 \)). Two 3D PET datasets combined (\( n = 252 \)) were used for training and validation of an elastic net regularized generalized logistic regression model (GLM) based on a selection of clinical and robust independent PET radiomics features (GLM\(_{\text{all}}\)). The fitted model performance was externally validated (\( n = 40 \)). The performance of GLM\(_{\text{all}}\) (measured with area under the receiver operating characteristic curve, AUC) was highest in predicting 2-year overall survival (0.66±0.07). No significant improvement was observed for GLM\(_{\text{all}}\) compared to a model containing only PET radiomics features or only clinical variables for any clinical endpoint. External validation of GLM\(_{\text{all}}\) led to AUC values no higher than 0.55 for any clinical endpoint. In this study, robust independent FDG PET radiomics features did not have complementary value in predicting survival endpoints in lung cancer patients. Improving risk stratification and clinical decision making based on clinical variables and PET radiomics features has still been proven difficult in locally advanced lung cancer patients.

Introduction

Despite the emergence of new technologies and treatment options such as tyrosine kinase inhibitors targeted towards mutations, and immune checkpoint inhibitors, the global survival
of lung cancer patients has improved only gradually in the last decades [1–4]. Locally advanced non-small cell lung cancer (NSCLC) is a highly heterogeneous disease where only modest improvements in survival have been observed, with the exception of chemoradiotherapy (CRT) patients treated with the anti-PD-L1 antibody Durvalumab whose overall and progression-free survival significantly improved compared to those receiving CRT alone [5]. New approaches are urgently needed for the selection of treatment strategies for NSCLC patients, which are currently determined mainly by TNM staging [6, 7]. In addition to TNM staging, other well-established, reproducible, independent prognostic factors are used to guide clinicians in making treatment decisions, such as Eastern Cooperative Oncology Group (ECOG) performance status [8, 9], weight loss [10], and gender [11]. Numerous other biomarkers have been investigated, although less reproducible, such as histology [12], age [13], serum blood levels [14, 15], mutation status [16], and protein expression levels [17, 18]. In locally advanced NSCLC, treatment selection based on TNM staging and other clinical variables may not be accurate enough for survival probability prediction [19, 20]. Therefore, the search for more accurate reproducible independent prognostic factors is warranted in the context of personalized medicine.

A current field of interest is the assessment of quantitative image features and its complementary value to well-established clinical prognostic models. Radiomics has been introduced as a sophisticated way to extract and mine a large number of quantitative image features, primarily using anatomical CT information [21]. The basic assumption of radiomics is that underlying tumour biology could be captured [22]. This information may actually be better characterized with functional imaging such as $^{18}$F-fluorodeoxyglucose Positron Emission Tomography (FDG PET), the gold standard in NSCLC diagnosis and staging, which is able to characterize molecular heterogeneity in lung cancer [23, 24]. It is therefore worthwhile to investigate the prognostic performance of radiomics features from functional imaging such as PET.

Basic PET radiomics features have provided clinically relevant prognostic information for NSCLC patients. Examples include standardized uptake value (SUV) based metrics like maximum, peak, and mean SUV (SUV$_{\text{max}}$, SUV$_{\text{peak}}$, and SUV$_{\text{mean}}$, respectively), metabolic tumour volume (MTV), and total lesion glycolysis (TLG) [25–32]. The more advanced PET texture features employed for quantification of tumour heterogeneity, have also been reported to be of prognostic value [33–41]. However, the variable nature of PET imaging makes it difficult to reproduce these results [42, 43].

Furthermore, PET texture features can also be subject to differences in reconstruction settings and delineation methods [44], SUV binning methods [45, 46], and feature calculation methods [47]. It is not yet clear which PET radiomics features are insensitive to all of these factors, and also to what degree.

Regardless of the issues with variability, complementary PET radiomics features should be independent from well-known prognostic SUV metrics, such as MTV and SUV$_{\text{max}}$. Some investigators reported specific PET texture features that were associated with MTV [37, 39, 47, 48, 49]. In these cases, prognostic texture features would rather act as a surrogate than as an independent variable. Such an association is also not warranted for clinical variables. Hence, the relationship of PET texture features with well-known prognostic factors has to be thoroughly studied too.

With all the confounding factors described above, in combination with the high number of possible radiomics features, it is not surprising that false discovery rates are high amongst FDG PET and CT studies on texture features [50]. Without proven, robust, and independent prognostic PET texture features, it will be challenging to move further in the field. Therefore, this study aims to investigate the repeatability of PET radiomics features, and also assesses the
relationship with well-known prognostic factors in PET, such as MTV and SUV\textsubscript{max}. The rationale is to identify a group of radiomics features derived from pre-treatment PET imaging that are robust, independent, and prognostic, with possible additional value to current clinical prognostic variables.

**Materials and methods**

**Patient data**

Three NSCLC patient cohorts from the Netherlands Cancer Institute (NKI) and one from the Peter MacCallum Cancer Centre (PMCC) were included in this study to develop and validate a radiomics signature. Peter MacCallum Cancer Centre Ethics and Clinical Research Committee's approval was granted and all research was performed in accordance with relevant guidelines/regulations. Patient's written, informed consent was obtained. An overview of the datasets is given in Table 1. Patients were excluded if the primary tumour was smaller than 10 cc or if the patient had stage IV NSCLC at baseline. To detect brain metastases at baseline, the NKI patients were scanned with MR imaging and the PMCC performed FLT baseline scans before treatment.

The repeatability and independence of PET radiomics features was assessed using a 4D PET/CT dataset (4D PET lung) consisting of 70 stage III NSCLC patients. No clinical data was collected for these patients. The second cohort (NKI lung 1) contained 228 patients treated with concurrent chemoradiotherapy (CCRT) for stage IA-IIIC NSCLC in the NKI between 2007 and 2011 as described earlier [51]. The third cohort, also from the NKI (NKI lung 2), consisted of 24 patients with stage IIB-IIIC NSCLC treated between 2013 and 2016, similar as NKI lung 1. The fourth cohort was from the PMCC (PMCC lung 1) and involved 40 stage IB-IIIC NSCLC patients treated with CCRT as previously reported [32].

**Clinical endpoints for prognostic model**

The primary endpoint used for the prognostic model was two-year overall survival (2-year OS). Overall survival was defined as the time between the start of treatment and date of death. In addition, two-year progression-free survival (2-year PFS), one-year PFS (1-year PFS), one-year local recurrence-free survival (1-year LRS), and one-year distant metastases-free survival (1-year DMS) were also studied. Progression was defined as growth of tumour cells in the primary tumour or involved lymph nodes, or metastases to other organs, or death. LRS was defined as progression in the primary tumour and/or involved lymph nodes as assessed on follow-up scans. DMS was described according to the 8th edition of the TNM classification for NSCLC [52] as evaluated on follow-up scans.

**Data acquisition and image reconstruction**

Patients from the NKI lung 1 and 2 dataset both underwent a whole-body FDG PET/CT using a Gemini TF or Gemini TF Big Bore scanner (Philips Medical Systems, Cleveland, OH). The reconstruction voxel size of the PET data was $4 \times 4 \times 4$ mm$^3$. Patients fasted for at least 8 h to ensure low levels of serum glucose. Patients with a Body Mass Index (BMI) $\leq 28$ were intravenously injected with 190 MBq $^{18}$F-FDG, or 240 MBq in case of a BMI $>28$. Patients were scanned 60 minutes after injection of $^{18}$F-FDG. The acquisition time of the PET/CT scanner was 2 minutes per bed position.

In the PMCC lung 1 cohort, whole-body FDG PET/CT scans were acquired on a GE STE (GE Medical Systems, Milwaukee, WI) or Biograph (Siemens Medical Solutions, Erlangen, Germany) scanner. The reconstructed voxel size of the PET data was $4.3 \times 4.3 \times 3.3$ mm$^3$ for
the GE STE scanner, and $4.1 \times 4.1 \times 3.0 \text{ mm}^3$ for the Siemens Biograph scanner. Patients fasted for more than 6 hours before ${}^{18}$F-FDG scans. Patients were intravenously injected with $4.2 \text{ MBq/kg} ^{18}$F-FDG. Baseline emission scans were initiated 60 minutes after injection. The acquisition time of the PET/CT scanner was 3 minutes per bed position.

For the 4D PET lung dataset, scans were acquired on a Gemini TF scanner (Philips Medical Systems, Cleveland, OH). The reconstruction voxel size of the PET data was $4 \times 4 \times 4 \text{ mm}^3$. 

Table 1. Overview of the four patient cohorts used in the study. Unless otherwise stated, values represent the median with the range in parentheses. $\text{MTV}_{2.5} = \text{metabolic tumour volume obtained using a SUV threshold of 2.5, } \text{MTV}_{40} = \text{metabolic tumour volume obtained using a threshold of 40% of the maximum intensity, } \text{SUV}_{\text{max}} = \text{maximum SUV uptake, } \text{OS} = \text{overall survival, PFS = progression-free survival, LRS = local recurrence-free survival, DMS = distant metastases-free survival. Nos = not otherwise specified.}$

|                      | 4D PET lung | NKI lung 1 | NKI lung 2 | PMCC lung 1 |
|----------------------|-------------|------------|------------|-------------|
| No. of patients      | 70          | 228        | 24         | 40          |
| Age (year)           | n/a         | 64 (36–87) | 63 (39–82) | 68 (53–86)  |
| Gender               | n/a         |            |            |             |
| Male                 |             | 142        | 13         | 29          |
| Female               |             | 86         | 11         | 11          |
| Disease stage        | n/a         | IA-IIIC    | IIB-IIIC   | IB-IIIC     |
| IA                   | 1           |            | 0          | 0           |
| IB                   | 4           | 0          |            | 1           |
| IIA                  | 0           | 0          | 3          |             |
| IIB                  | 16          | 2          | 5          |             |
| IIIA                 | 102         | 7          | 15         |             |
| IIIB                 | 82          | 13         | 12         |             |
| IIIIC                | 23          | 2          | 4          |             |
| T stage              | n/a         |            |            |             |
| 1                    | 6           | 1          | 5          |             |
| 2                    | 78          | 4          | 24         |             |
| 3                    | 63          | 7          | 9          |             |
| 4                    | 81          | 12         | 2          |             |
| N stage              | n/a         |            |            |             |
| 0                    | 42          | 4          | 5          |             |
| 1                    | 20          | 2          | 5          |             |
| 2                    | 130         | 13         | 17         |             |
| 3                    | 36          | 5          | 13         |             |
| Histology            | n/a         |            |            |             |
| Adeno                | 80          | 12         | 16         |             |
| Squamous cell        | 83          | 7          | 13         |             |
| Large cell           | 8           | 1          | 5          |             |
| Nos or other         | 57          | 4          | 6          |             |
| GTV (cc)             | n/a         | 118 (15–906) | 84 (10–351) | 49 (12–544) |
| $\text{MTV}_{2.5}$ (cc) | 62 cc (10–545) | 72 (10–693) | 91 (11–337) | 51 (8–478) |
| $\text{MTV}_{40}$ (cc) | 27 cc (4–169)  | 31 (3–394)  | 34 (5–289)  | 31 (4–378)  |
| $\text{SUV}_{\text{max}}$ | 11.5 (4.3–55.1) | 14.6 (5.9–44.8) | 15.7 (6.9–28.3) | 16.5 (6.3–33.2) |
| Median follow-up time (months) | n/a | 17 | 22 | 24 |
| 2-year OS            | n/a         | 40%        | 46%        | 54%         |
| 2-year PFS           | n/a         | 29%        | 21%        | 20%         |
| 1-year PFS           | n/a         | 50%        | 54%        | 35%         |
| 1-year LRS           | n/a         | 58%        | 71%        | 47%         |
| 1-year DMS           | n/a         | 54%        | 54%        | 45%         |

https://doi.org/10.1371/journal.pone.0228793.t001
The 4D PET/CT data were reconstructed in 10 phases, and the attenuation in each frame of the 4D PET data was corrected with the corresponding 4D CT frame. The acquisition time of the 4D PET was kept the same as that used for 3D PET [52].

Mid-position scans from 4D PET lung dataset for repeatability testing

The 4D PET/CT data were reconstructed in 10 phases, and from these phases two new mid-position scans were derived [53]. The first mid-position scan was created from the even phases (0, 2, 4, 6, and 8) and is named 'Mid-P even', and the odd phases (1, 3, 5, 7, and 9) were used to create the second mid-position scan 'Mid-P odd'. The even and odd number of frames were selected to keep the amount of tumour motion balanced in both scans. Fig 1 gives an overview of the workflow.

The source of variability was different in these two mid-position scans compared to a test-retest setting, since the biological tumour variability has been eliminated. In this case, the variability was mostly caused by minor differences in noise levels and tumour motion, hence robust quantitative features should not differ substantially in outcome.

Tumour segmentation

For each patient in the NKI lung 1, NKI lung 2, and PMCC lung 1 cohort, a volume-of-interest (VOI) enveloping the primary tumour was manually drawn by radiation oncologists using information from both PET and CT imaging. From this VOI, the MTV was auto-segmented

Fig 1. Workflow of the PET mid-position scans. A 4D PET scan was loaded for each patient consisting of 10 frames, where the odd or even number of frames were selected. A 4D deformation vector field (DVF) was applied to these frames to deform them to the mid-position. Lastly, the mean of the 5 deformed frames was calculated to obtain the PET mid-position scan. For comparison, the PET mid-position scan obtained from 10 frames has been included in the image too. Mid-P = PET mid-position scan.

https://doi.org/10.1371/journal.pone.0228793.g001
on the FDG PET scan. Two auto-segmentation methods were applied: a metabolic tumour region delineation that included all voxel intensities above 2.5 (SUV$_{2.5}$), and a high intensity delineation that included all voxel intensities that were at least 40% of the SUV$_{\text{max}}$ (SUV$_{40}$). Auto-segmentation was performed with in-house developed software named Match42 (version 1.0.0) using a Python plug-in. The metabolic tumour volume obtained from SUV$_{2.5}$ and SUV$_{40}$ were named MTV$_{2.5}$ and MTV$_{40}$, respectively. In the 4D PET lung dataset, a VOI was manually drawn around the primary tumour in one PET mid-position scan, and copied to the second PET mid-position scan. The auto-segmentation was performed on both PET mid-position scans independently.

**PET radiomics features**

The Pyradiomics toolkit was used for radiomics feature extraction [54]. With this toolkit a total of 105 features were available for feature calculations. These were divided into 18 first-order features, 13 shape features (including metabolic tumour volume), and 74 texture features describing the spatial distribution of voxel intensities. The texture features were derived from the gray level co-occurrence matrix (GLCM; 23 features) [55], gray level run-length matrix (GLRLM; 16 features) [56], gray level size-zone matrix (GLSZM; 16 features) [57], gray level dependence matrix (GLDM; 14 features) [58], and neighbourhood gray tone difference matrix (NGTDM; 5 features) [59]. The mathematical definitions of these features were in compliance with feature definitions as described by the Imaging Biomarker Standardization Initiative (IBSI) [60].

**SUV discretization and matrix calculation**

Before texture features were extracted, pre-processing steps were required in the form of SUV binning and matrix definition. SUV discretization is an intensity-resampling step, before building the texture matrices on which texture features rely. SUV discretization or binning was applied with the fixed bin count method (e.g. 64 bins) and an alternative method using a fixed bin width (e.g. 0.25 SUV). All texture features were calculated from a single matrix taking into account all 13 directions simultaneously. A more detailed description on SUV binning and matrix calculation can be found in S1 File, respectively.

**Repeatability**

The repeatability assessment was performed within the same patient comparing two different PET mid-position scans. For each patient, the PET mid-position scan obtained from the even numbered frames (Mid-P even) was compared with the PET mid-position scan from the odd numbered frames (Mid-P odd). This resulted in four comparisons: 2 SUV binning methods and 2 thresholding methods were applied.

The repeatability of each PET radiomics feature was assessed with the Coefficient of Repeatability (CR) [61]. See S1 File for more details. The CR was reported as a percentage: $100\% \times \frac{\text{CR}}{\text{mean}}$, where mean is the average of the PET radiomics feature value within the patient cohort. The threshold for poor repeatability was set to a value of 30%, corresponding to PET Response Criteria in Solid Tumours (PERCIST) [62].

**Independence testing**

To determine whether the features were correlated with the two commonly reported prognostic PET features MTV and SUV$_{\text{max}}$, the Spearman’s rank correlation coefficient ($\rho$) was calculated on one of the Mid-P scans, using the same set-up as for the repeatability testing. PET
radiomics features that had $|\rho| \geq 0.5$ were considered to have a correlation with MTV or SUV$_\text{max}$, and were discarded from further analysis. The choice of $|\rho| < 0.5$ as limit for independent features was validated with the ‘elbow method’ using hierarchical clustering [63].

An overview of the radiomics workflow and feature selection procedure is given in Fig 2.

**Model training**

An elastic net regularized generalized logistic regression model (GLM) was built with PET radiomics features derived from pre-treatment PET imaging (GLM$_\text{rad}$). To increase the sample size in the training and test sets, for the purpose of building a GLM, NKI lung 1 and lung 2 were combined. In this study, 80% of the NKI data was used for training the model, and 20% for validation. Different ratios of training/validation were also tested, but were not reported as there was no major differences seen in the results. Elastic net regression analysis using the R package ‘glmnet’ was performed on the training set [64]. With 20-fold cross validation (CV), the most optimal fitted GLM$_\text{rad}$ with minimal CV error was determined and selected for model validation.

**Model validation**

To validate the fitted model of the training set, the area under the receiver operating characteristic curve (AUC) was calculated between the predicted outcome and the observed outcome in the validation set. To reduce randomness introduced by selecting a random subset of the complete data for training and validation, the procedure for model training and validation was
repeated 100 times. This yields a better estimate of the true validation set performance by randomly simulating many scenarios with varying training and validation set compositions [65]. From the 100-times-repeated training/validation procedure, results were averaged, and the best performing GLM_{rad} was externally validated for each clinical endpoint on PMCC lung 1. During 100-times-repeated training/validation procedure, per iteration, the fitted model was stored to keep track of the PET radiomics features that were selected by elastic net in the fitted model [66]. PET radiomics features and clinical variables were ranked based on the frequency of inclusion in the fitted model.

Model comparison

Clinical variables such as PET/CT-based GTV, TNM staging, histology, gender, and age were also introduced into the radiomics signature to create a prognostic model containing PET radiomics features and clinical variables (GLM_{all}). In addition, a model based on only the clinical variables was calculated using elastic net regression (GLM_{clin}). To assess the complementary value of PET radiomics features with clinical variables, the mean AUC was calculated from 100 iterations for each model and compared. The Mann Whitney U Test was used to assess any significant differences between the predictive performance of GLM_{all}, GLM_{clin}, and GLM_{rad}, and p-values below 0.05 were seen as significant.

Results

Repeatability

Results of the repeatability test were based on the 4D PET lung dataset and an overview of notable PET radiomics features and their corresponding CR is given in Table 2. All first-order features were repeatable when extracted from MTV_{2.5} irrespective of SUV binning method. In contrast, 13 out of 18 first-order features were repeatable when extracted from MTV_{40}. Furthermore, around 50 texture features were repeatable when extracted from MTV_{2.5} regardless of SUV discretization method, versus 28 repeatable texture features extracted from MTV_{40}. With regards to shape features, only MTV_{40} was not repeatable.

Amongst the four comparisons, 211 out of 360 PET radiomics features were repeatable. An overview of all PET radiomics features and their corresponding CR is given in S1 File. The impact of large delineation inaccuracies on repeatability was studied between contours generated by the two different SUV thresholds, though only reported as supplementary data (S1 File).

Relationship of PET radiomics features with MTV and SUV_{max}

The Spearman’s Rank correlation coefficient was calculated to assess the relationship of 211 repeatable PET radiomics features with MTV and SUV_{max}. Four assessments were performed in total on one of the mid-position scans, with groups consisting of a combination of either one of the SUV binning methods and one of the tumour volumes (MTV_{2.5} or MTV_{40}). Not all repeatable PET radiomics features were found to be independent from MTV and SUV_{max}. From the first-order features, only Kurtosis and Skewness extracted from MTV_{2.5} were independent from MTV and SUV_{max}. There were no independent repeatable first-order features for MTV_{40}. Regarding the fixed bin count method, 17 out of 50 texture features extracted from MTV_{2.5} were independent from MTV and SUV_{max}. There were no independent repeatable first-order features for MTV_{40}. Regarding the fixed bin count method, 17 out of 50 texture features extracted from MTV_{2.5} were not strongly associated with MTV and SUV_{max}. This also counted for 5 texture features extracted from MTV_{40}. With regards to the fixed bin width method, there were no texture features independent from either SUV_{max} or MTV. Elongation, Flatness, and Sphericity were the only independent shape features when extracted from MTV_{2.5}, though only...
Elongation and Flatness remained independent for MTV_{40}. A complete overview of independence testing for all PET radiomics features is given in S1 File.

An overview of correlations amongst the selected robust independent PET radiomics features and clinical variables is given in Fig 3. More details on robust and independent PET radiomics features can be viewed in S1 File. The robust independent PET radiomics features did not show any strong correlation with the other clinical variables, such as age, ECOG PS, gender, histology, and TNM stage. However, there were associations present amongst the PET texture features.

Building the radiomics signature

Based on the feature selection criteria, 31 PET radiomics features were selected for the next steps (see Fig 3). Three elastic net regularized GLMs were built per endpoint: GLM_{rad}, GLM_{clin}, and GLM_{all}. Results of the model performances are shown in Fig 4, showing that GLM_{rad} does not significantly outperform GLM_{clin} for any clinical endpoints. The GLM_{clin} has a significantly better predictive performance compared to GLM_{rad} in 2-year OS (p<0.0001), and in 1-year LRS (p<0.001). GLM_{all} did not show a significantly better performance to both GLM_{rad} and GLM_{clin} simultaneously in any endpoint. External validation of GLM_{all} led to AUC values ranging from 0.51 to 0.59 for any clinical endpoint. When GLM_{clin} was externally validated, the highest predictive performance was 0.60 for 2 year OS. For GLM_{rad}, the highest predictive performance was 0.71 for 2-year PFS.

Table 2. An overview of categorized notable PET radiomics features that are commonly reported in literature with their coefficient of repeatability (CR, %). The asterisk (*) represents features that were repeatable in all four different settings. Per category, the total number of PET radiomics features that met the study repeatability criterion is added.
Promising features

Table 3 shows selected features for each fitted GLM, and how frequent these features were chosen in the fitted model over 100 iterations. The feature shape Sphericity was present in 100% of the iterations for 2-year OS. From the 100 repetitions, GLCM ClusterTendency was selected in more than 95% for predicting 1-year PFS and 1-year DMS. Clinical variables such as age and GTV were prominent in predicting 2-year OS and 1-year LRS, next to shape Sphericity. As can be seen in Table 3, age, shape Sphericity, and GLCM ClusterTendency are present amongst the most selected features for all clinical endpoints.

Discussion

The rationale of this study was to identify a group of FDG PET radiomics features for NSCLC patients that are robust, independent, prognostic, and complementary to well-established clinical variables. We found PET radiomics features that met the study criteria of robustness and independence, and that also exhibited prognostic value. However, results demonstrated that PET radiomics features are not complementary to clinical variables for predicting clinical
endpoints in NSCLC patients that were treated with CCRT. This indicates that clinical variables provide more prognostic information than robust independent PET radiomics features, and that the prognostic value in PET radiomics features is minimal. This study did take into account shortcomings of other studies on PET radiomics features [50] with the use of a feature selection method that reduces overfitting and external validation of results.

Feature selection based on the repeatability of PET radiomics features was feasible with the use of different phases from 4D PET imaging, in the absence of test-retest data. Larue et al. showed that in 4D CT, the majority of the features have a high agreement between radiomics feature stability based on 4D CT and test–retest data in lung cancer [67]. It was therefore hypothesized that 4D PET scans could also be used for repeatability testing. To determine robust PET radiomics features, a CR of 30% was chosen as limit for repeatability, based on PERCIST. However, a limitation of using 4D PET for repeatability testing is the absence of biological tumour variability, and PERCIST takes this variability into account. Hence, the use of a 30%-limit could be seen as too tolerant, and 15%, as commonly used in phantom studies, could be more appropriate. Even under these stricter circumstances, 12 first-order features, 24 out of 74 texture features, and all shape features would still meet that criterion as can be seen in S1 File. Besides that, the most prominent PET radiomics features in the fitted GLMs were SUV_max (CR = 13.2%), shape Sphericity (CR = 3.2%), GLCM ClusterTendency (CR = 21.9%), GLRLM GrayLevelNonUniformityNormalized (CR = 18.4%), and MTV_{2.5} (CR = 5.9%) as seen in Table 3. This shows that repeatable PET radiomics features with a CR > 15% are also
Table 3. The most selected features in the model by elastic net, ranked by the number of times selected in the generalized linear model. Only the top 10 most selected PET radiomics are shown. The features written in italic bold are present in all endpoints.

| Endpoint | GLM selected features by elastic net | Frequency |
|----------|-------------------------------------|-----------|
| 2-year OS | Age | 100 |
|          | GTV | 100 |
|          | Shape_Sphericity | 100 |
|          | MTV2.5 | 78 |
|          | glem_ClusterTendency | 56 |
|          | SUV_max | 39 |
|          | Gender | 34 |
|          | glem_JointEntropy | 34 |
|          | glem_GrayLevelNonUniformityNormalized | 33 |
|          | glem_GrayLevelVariance | 29 |
| 2-year PFS | Age | 50 |
|           | SUV_max | 50 |
|           | glem_GrayLevelNonUniformityNormalized | 49 |
|           | shape_Sphericity | 47 |
|           | Histology | 42 |
|           | MTV2.5 | 38 |
|           | glem_ClusterTendency | 30 |
|           | N_status | 28 |
|           | T_status | 25 |
|           | shape_Elongation_MTV40 | 20 |
| 1-year PFS | GTV | 99 |
|           | glem_ClusterTendency | 95 |
|           | shape_Sphericity | 76 |
|           | Age | 63 |
|           | T_status | 49 |
|           | MTV2.5 | 40 |
|           | glem_SumEntropy_MTV40 | 39 |
|           | shape_Elongation | 37 |
|           | SUV_max | 31 |
|           | Histology | 29 |
| 1-year LRS | GTV | 83 |
|           | Age | 82 |
|           | glem_ClusterTendency | 65 |
|           | glem_SumEntropy_MTV40 | 63 |
|           | shape_Sphericity | 57 |
|           | Gender | 48 |
|           | glem_GrayLevelVariance | 47 |
|           | N_status | 27 |
|           | Stage | 25 |
|           | glem_GrayLevelVariance | 24 |
| 1-year DMS | GTV | 99 |
|           | glem_ClusterTendency | 96 |
|           | shape_Sphericity | 57 |
|           | MTV2.5 | 52 |
|           | Histology | 34 |
|           | T_status | 33 |
|           | Age | 32 |
|           | glem_SumEntropy_MTV40 | 32 |
|           | shape_Elongation | 29 |
|           | SUV_max | 23 |
frequently present in the fitted models. Even though there is literature reporting on stability of PET radiomics features in a test-retest setting [45, 46], there is no objective limit for the level of repeatability for each PET radiomics feature. Determining such an objective limit is only relevant if the studied PET radiomics feature contains clinically useful information. Hence, in the absence of an objective limit for each PET radiomics feature, the 30%-limit of PERCIST was applied to all.

It was observed that the repeatability for features from MTV2.5 is better compared to MTV40 and this is due to two important factors:

1. From the 13 shape features, only MTV40 had a CR >30% when comparing the MTV40 between two mid-position scans. This variance, of course, has already a great impact on PET radiomics features calculated from MTV40 as it is known that differences in delineation have an impact on feature outcome [44].

2. Radiomics features are calculated on matrices which dimensions are dependent on the SUV range. With MTV2.5 matrix dimensions are more standardized than MTV40, which is dependent on the maximum SUV (CR = 13.2%).

In this case, the use of MTV2.5 for GTV delineation may be advised over MTV40 in PET radiomics analysis.

Another step of the feature selection procedure was to assess the independence of PET radiomics features, to identify possible prognostic features that could complement basic SUV metrics and volumetric features. In this context, changes in PET radiomics features would be independent from changes in basic SUV metrics and volume, increasing their utility in longitudinal studies. Therefore, the use of a fixed bin width for SUV binning should be avoided as this method resulted in PET radiomics features that were all strongly correlated to either maximum SUV or MTV. While the choice of |\rho|<0.5 for independence testing may seem arbitrary, a |\rho|<0.7 was also studied and did not improve results (see S1 File for more details). Independence testing had the most impact in the feature pre-selection procedure as it resulted in a substantial decrease of PET radiomics features. Unfortunately, results demonstrated that independence testing could not guarantee that remaining robust independent PET radiomics features exhibited complementary value next to clinical variables. Even so, we strongly advise assessing the relationship of radiomics features with current established prognostic factors in any study considering PET radiomics features for prognostication as this is the first important step in showing their potential added value in the clinic.

A final selection of features in the GLM was performed by elastic net regression, robust to collinearity amongst features [66]. More feature selection/classification methods exist [68], though comparing multiple methods was beyond the scope of this study. However, in literature, elastic net regression yielded one of the highest discriminative performances in chemoradiotherapy outcome prediction in 12 patient datasets containing in total 1053 lung cancer patients [65]. Interestingly, elastic net regression could also be used as a standalone feature selection method. A comparison of the feature selection method based on repeatability, independence, and elastic net regression (GLM_{all}), and a method using only elastic net regression (GLM_{elnet}) was performed, see S1 File. Pre-selection of PET radiomics features is worthwhile, because the number of PET radiomics features in GLM_{elnet} was often high (>20 features) and many were highly correlated to volume or SUV_{max}. In contrast, the average number of features in GLM_{all} was 9. Even so, it was observed that elastic net tends to keep all of the correlated and presumably prognostic features in the fitted model or shrinks all to zero, whereby increasing the number of (correlated) features resulted in a decrease of the predictive performance. This decrease of predictive performance seen in the validation set suggests that overfitting, although
reduced, may still be present. This shows the value of dimensionality reduction in order to optimize predictive performance in rather small sample sizes.

The predictive performance of PET texture features in NSCLC has been studied widely, but clear evidence that PET texture features are complementary to clinical variables is lacking [69]. This study has extensively studied PET texture features and did not find any evidence for added value next to current clinical variables. S1 File provides a complete overview of all assessed model performances, including additional investigations with TLG. In literature, typically, only one or two PET texture features have been significantly associated with predicting various survival endpoints [39–41, 47, 70–72]. However, of all the prognostic PET texture features from those studies, such as GLCM Joint Entropy, Correlation, Contrast, Dissimilarity (or Difference Average), NGTDM Coarseness, Busyness, and Contrast, only GLCM Joint Entropy was both repeatable and independent from SUV$_{max}$ or volume in our dataset. In this study, GLCM Joint Entropy was selected 34 times out of 100 by elastic net regression for predicting 2-year OS, and its value in overall survival was also previously shown [47]. Nonetheless, in our study the average predictive performance for GLM$_{all}$ in all clinical endpoints ranged from 0.50 to 0.66. For comparison, other studies predicting outcome with both PET radiomics and clinical variables in NSCLC found predictive performances of 0.63 for predicting OS [41], 0.72 for local recurrence [71], and 0.71 for distant metastases [72]. Even with those results, neglecting any limitations of those studies, there is still no strong evidence that PET texture features exhibit complementary information.

Results from the external validation demonstrated even lower AUC values in most cases than the internal validation set. Besides the limitation of the use of a small external dataset, differences were observed between institutes regarding patients, treatment, and image acquisition and reconstruction settings, that also can influence outcome [44, 73], and could have resulted in poor generalizability. To overcome the issue of poor generalizability, a prognostic model should be trained on a combination of well-balanced patient cohorts from multiple institutes, and PET acquisition and reconstruction protocols should be harmonized across centers in multi-centre studies. Alternatively, a post-reconstruction harmonization method proposed by Orlhac et al. may also aid in removing the multicenter effect for textural features and SUV [74].

Furthermore, limitations of this paper include the relatively small sample size for machine learning methods that could have affected the predictive performance [75], and the impact of tumour motion on PET radiomics features, especially in lower lobe tumours [76]. Although Grootjans et al. showed that there are specific PET radiomics features whose prognostic accuracy was not affected by respiratory motion and varying noise-levels [29].

To overcome the limitations of this study, and to be certain that there is no complimentary information in PET radiomics features, future studies need to set up large scale multi-centre cohorts to allow for multiple independent validation datasets. To further improve predictive performance, studies could investigate elastic net-Cox proportional hazard models [77], non-linear relationships by applying data transformation on PET radiomics features [21, 78, 79], or assess computer engineered features with neural networks or deep learning networks [80, 81]. Currently, deep learning is under investigation for use in lung nodule detection, tumour segmentation, and tumour classification with histopathology images [82]. Its use in medical image analysis is increasing as algorithms become more sophisticated and more data becomes available, which might lead to new insights in survival prediction. A step further would be to combine radiomics features from multimodal imaging such as PET, CT and MRI [83, 84], where the combination of anatomical and biological features may of added value for providing a personalized treatment strategy.
Conclusion
In this study, robust independent PET radiomics features, identified with 4D PET imaging, did not have complementary value in predicting overall survival and progression-free survival in NSCLC patients treated with concurrent chemoradiotherapy. Improving risk stratification and clinical decision making based on clinical variables and PET radiomics features has still been proven difficult in locally advanced lung cancer patients. New approaches should be investigated in large scale multi-centre studies to deal with current challenges in the field of radiomics before translation to the clinic becomes realistic.

Supporting information
S1 File.
(DOCX)

Acknowledgments
The authors would like to thank Simon van Kranen and Jonas Teuwen for helping out with programming, Michel van den Heuvel for providing NKI lung 1 dataset, Natascha Bruin for providing delineations and clinical data for the NKI lung 2 dataset, and Erik Vegt, Rod Hicks, Nick Hardcastle, David Ball, and Tomas Kron for scientific editing of the manuscript.

Author Contributions
Conceptualization: Tom Konert, Sarah Everitt, Matthew D. La Fontaine, Jeroen B. van de Kamer, Wouter V. Vogel, Jan-Jakob Sonke.
Data curation: Tom Konert, Sarah Everitt, Jeroen B. van de Kamer, Jason Callahan.
Formal analysis: Tom Konert.
Investigation: Tom Konert.
Methodology: Tom Konert, Jeroen B. van de Kamer, Jan-Jakob Sonke.
Project administration: Tom Konert.
Resources: Tom Konert.
Software: Tom Konert, Matthew D. La Fontaine.
Supervision: Matthew D. La Fontaine, Wouter V. Vogel, Jan-Jakob Sonke.
Validation: Tom Konert, Jan-Jakob Sonke.
Visualization: Tom Konert.
Writing – original draft: Tom Konert.
Writing – review & editing: Sarah Everitt, Matthew D. La Fontaine, Jeroen B. van de Kamer, Michael P. MacManus, Wouter V. Vogel, Jason Callahan, Jan-Jakob Sonke.

References
1. Aupérin A, Le Péchoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small cell lung cancer. J Clin Oncol 2010; 28: 2181–90. https://doi.org/10.1200/JCO.2009.26.2543 PMID: 20351327
2. Ferlay J, Soerjomataram I, Dikshil R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136(5): 359–86.
3. Chan BA, Hughes BGM. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res 2015; 4(1): 36–54. https://doi.org/10.3978/j.issn.2218-6751.2014.05.01 PMID: 2506345

4. Remon J, Vilariño N, Reguart N. Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): Approaches on special subgroups and unresolved burning questions. Cancer Treat Rev 2018; 64:21–29. https://doi.org/10.1016/j.ctrv.2018.02.002 PMID: 2945155

5. Antonia SJ, Villegas A, Daniel D, et al.; PACIFIC Investigators. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med 2018. [Epub ahead of print]

6. Deterbeck FC, Boffa DJ, Kim AW, et al. The Eighth Edition Lung Cancer Stage Classification. Chest 2017; 151(1): 193–203. https://doi.org/10.1016/j.chest.2016.10.010 PMID: 27780786

7. Rami-Porta R, Bolejack V, Ginoux DJ, et al, and International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Board Members and Participating Institutions. The IASLC Lung Cancer Staging Project: the new database to inform the eighth edition of the TNM classification of lung cancer. J Thorac Oncol 2014; 9: 1618–1624. https://doi.org/10.1097/JTO.0000000000000334 PMID: 25436796

8. Paesmans M. Prognostic and predictive factors for lung cancer. Breathe.2012; 9: 112–121.

9. Berghmans T, Paesmans M, Sculier JP. Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables. Ther Adv Med Oncol 2011; 3: 127–138. https://doi.org/10.1177/1758834011401951 PMID: 21904576

10. Nakamura H, Ando K, Shinmyo T, et al. Female gender is an independent prognostic factor in non-small cell lung cancer: a meta-analysis. Ann Thorac Cardiovasc Surg 2011; 17: 469–480. https://doi.org/10.5761/atcs.0a.10.0163 PMID: 21881356

11. Yu Z, Zhang G, Yang M, et al. Systematic review of CYFRA 21–1 as a prognostic indicator and its predictive correlation with clinicopathological features in Non-small Cell Lung Cancer: A meta-analysis. Oncotarget 2017; 8(3): 4043–4050. https://doi.org/10.18632/oncotarget.14022 PMID: 28081412

12. Yu KH, Zhang C, Berry GJ, et al. Predicting non-small cell lung cancer prognosis by fully automated microscopic pathology image features. Nat Commun 2016; 7(7): 12474.

13. Pallis AG, Gridelli C. Is age a negative prognostic factor for the treatment of advanced/metastatic non-small-cell lung cancer? Cancer Treat Rev 2010; 36(5): 436–440. https://doi.org/10.1016/s0169-5002(10)00007-4 PMID: 20092951

14. Jiang AG, Chen HL, Lu HY. The relationship between Glasgow Prognostic Score and serum tumour markers in patients with advanced non-small cell lung cancer. BMC Cancer 2015; 15: 386. https://doi.org/10.1186/s12885-015-1403-x PMID: 25956556

15.ials E, Paesmans M, Berghmans T, et al. Role of p53 as prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 2001; 18: 705–719. https://doi.org/10.1183/09031936.01.00062201 PMID: 11716177

16. Tong J, Sun X, Cheng H, et al. Expression of p16 in non-small cell lung cancer and its prognostic significance: a meta-analysis of published literatures. Lung Cancer. 2011; 74: 155–163. https://doi.org/10.1016/j.lungcan.2011.04.019 PMID: 21621871

17. Martin B, Paesmans M, Mascaux C, et al. KI-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer. 2004; 91: 2018–2025. https://doi.org/10.1038/sj.bjc.6602233 PMID: 15545971

18. Strom HH, Bremnes RM, Sundstrom SH, et al. Poor prognosis patients with inoperable locally advanced NSCLC and large tumours benefit from palliative chemoradiotherapy: a subset analysis from a randomized clinical phase III trial. J Thorac Oncol 2014; 9: 825–33. https://doi.org/10.1097/JTO.0000000000000184 PMID: 24807158

19. Mahar AL, Compton C, McShane LM, et al, on behalf of the Molecular Modellers Working Group of the American Joint Committee on Cancer. Refining prognosis in lung cancer: A report on the quality and relevance of clinical prognostic tools. J Thorac Oncol 2015; 10(11): 1576–1589. https://doi.org/10.1097/JTO.0000000000000652 PMID: 26313682

20. Aerts HJ, Velazquez ER, Leijenaar RT, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 2014; 5: 4006. https://doi.org/10.1038/ncomms5006 PMID: 24892406

21. Lambin P, Rios-Velazquez E, Leijenaar R, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012; 48(4): 441–6. https://doi.org/10.1016/j.ejca.2011.11.036 PMID: 22257792
23. Szyszko TA, Yip C, Szlosarek P, et al. The role of new PET tracers for lung cancer. Lung Cancer 2016; 94: 7–14. https://doi.org/10.1016/j.lungcan.2016.01.010 PMID: 26973200

24. Cremonesi M, Gilardi L, Ferrari ME, et al. Role of interim 18F-FDG-PET/CT for the early prediction of clinical outcomes of Non-Small Cell Lung Cancer (NSCLC) during radiotherapy or chemoradiotherapy. A systematic review. Eur J Nucl Med Mol Imaging 2017; 44(11): 1915–1927. https://doi.org/10.1007/s00259-017-3762-9 PMID: 28681192

25. Dingemans AM, de Langen AJ, van den Boogaart V, et al. First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging. Ann Oncol 2011; 22(3): 559–66. https://doi.org/10.1093/annonc/mdq391 PMID: 20702788

26. Mileshkin L, Hicks RJ, Hughes BG, et al. Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib. Clin Cancer Res 2011; 17(10): 3304–15. https://doi.org/10.1158/1078-0432.CCR-10-2763 PMID: 21364032

27. Hyun SH, Ahn HK, Kim H, et al. Volume-based assessment by (18)F-FDG PET/CT predicts survival in patients with stage III non-small-cell lung cancer. Eur J Nucl Med Mol Imaging 2014; 41(1): 50–8. https://doi.org/10.1007/s00259-013-2530-8 PMID: 23948859

28. Moon SH, Cho SH, Park LC, et al. Metabolic response evaluated by 18F-FDG-PET/CT as a potential screening tool in identifying a subgroup of patients with advanced non-small cell lung cancer for immediate maintenance therapy after first-line chemotherapy. Eur J Nucl Med Mol Imaging 2013; 40(7): 1005–13. https://doi.org/10.1007/s00259-013-2400-4 PMID: 23985109

29. Grootjans W, Tixier F, van der Vos CS, et al. Correlation of intra-tumour heterogeneity on 18F-fluorodeoxyglucose positron emission tomography imaging in patients with non-small cell lung cancer associated with worse survival. Int J Radiat Oncol Biol Phys 2014; 87: 55–58. https://doi.org/10.1016/j.radonc.2008.02.002 PMID: 18328584

30. Weiss GJ, Ganeshan B, Miles KA, et al. Noninvasive image texture analysis differentiates K-ras mutation from pan-wildtype NSCLC and is prognostic. PLoS ONE. 2014; 9(7): e100244. https://doi.org/10.1371/journal.pone.0100244 PMID: 24987838

31. Salavati A, Duan F, Snyder BS, et al. Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial. Eur J Nucl Med Mol Imaging 2017; 44(12): 1969–1983. https://doi.org/10.1007/s00259-017-3753-x PMID: 28688921

32. Everett S, Ball D, Hicks RJ, Callahan J, Plumridge N, Trinh J, et al. Prospective study of serial imaging comparing fluorodeoxyglucose positron emission tomography (PET) and fluorothymidine PET during radical chemoradiation for non-small cell lung cancer: reduction of detectable proliferation associated with worse survival. Int J Radiat Oncol Biol Phys 2017; 99:947–55.

33. Salavati A, Duan F, Snyder BS, et al. Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial. Eur J Nucl Med Mol Imaging 2017; 44(12): 1969–1983. https://doi.org/10.1007/s00259-017-3753-x PMID: 28688921

34. Paesmans M, Berghmans T, Dusart M, et al; European Lung Cancer Working Party, and on behalf of the IASLC Lung Cancer Staging Project. Primary tumour standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project. J Thorac Oncol. 2010; 5 (5): 612–9. https://doi.org/10.1097/JTO.0b013e3181d0a4f5 PMID: 20234323

35. Paesmans M, Berghmans T, Dusart M, et al; European Lung Cancer Working Party, and on behalf of the IASLC Lung Cancer Staging Project. Primary tumour standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project. J Thorac Oncol. 2010; 5 (5): 612–9. https://doi.org/10.1097/JTO.0b013e3181d0a4f5 PMID: 20234323

36. Del Gobbo A, Pellegrinelli A, Gaudioso G, et al. Analysis of NSCLC tumour heterogeneity, proliferative and 18F-FDG PET indices reveals Ki67 prognostic role in adenocarcinomas. Histopathology 2016; 68 (5): 746–51. https://doi.org/10.1111/his.12808 PMID: 26272457

37. van Baardwijk A, Bosmans G, van Suylen RJ, et al. Correlation of intra-tumour heterogeneity on 18F-FDG PET with pathologic features in non-small cell lung cancer: a feasibility study. Radiother Oncol 2008; 87: 55–58. https://doi.org/10.1016/j.radonc.2008.02.002 PMID: 18328584

38. Salavati A, Duan F, Snyder BS, et al. Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial. Eur J Nucl Med Mol Imaging 2017; 44(12): 1969–1983. https://doi.org/10.1007/s00259-017-3753-x PMID: 28688921

39. Del Gobbo A, Pellegrinelli A, Gaudioso G, et al. Analysis of NSCLC tumour heterogeneity, proliferative and 18F-FDG PET indices reveals Ki67 prognostic role in adenocarcinomas. Histopathology 2016; 68 (5): 746–51. https://doi.org/10.1111/his.12808 PMID: 26272457
40. Pyka T, Bundschuh RA, Andratschké N, et al. Textural features in pre-treatment [F18]-FDG-PET/CT are correlated with risk of local recurrence and disease-specific survival in early stage NSCLC patients receiving primary stereotactic radiation therapy. Radiat Oncol 2015; 10:100. https://doi.org/10.1186/s13014-015-0407-7 PMID: 25900186

41. Ohri N, Duan F, Snyder BS, et al. Pre-treatment FDG PET Textural Features in Locally Advanced NSCLC Secondary Analysis of ACRIN 6668/RTOG 0235. J Nucl Med. 2016; 57(6): 842–8. https://doi.org/10.2967/jnumed.115.166934 PMID: 26912429

42. Keyes JW Jr. SUV: standard uptake or silly useless value? J Nucl Med 1995; 36(10): 1836–9. PMID: 7562051

43. de Jong EEC, van Elmpt W, Hoekstra OS, et al. Quality assessment of positron emission tomography scans: recommendations for future multicenter trials. Acta Oncol 2017; 56(11): 1459–1464. https://doi.org/10.1080/0284186X.2017.1346824 PMID: 28830270

44. van Velden FHP, Kramer GM, Frings V, et al. Repeatability of Radiometric Features in Non-Small-Cell Lung Cancer [18F]FDG-PET/CT Studies: Impact of Reconstruction and Delineation. Mol Imaging Biol. 2016; 18(5): 788–795. https://doi.org/10.1007/s11307-016-0940-2 PMID: 26920355

45. Leijenaar RTH, Nalbantov G, Carvalho S, et al. The effect of SUV discretization in quantitative FDG-PET radiomics: the need for standardized methodology in tumour texture analysis. Sci Rep 2015; 5:11075. https://doi.org/10.1038/srep11075 PMID: 26242464

46. Desserolli MC, Ticier F, Weber WA, et al. Reliability of PET/CT Shape and Heterogeneity Features in Functional and Morphologic Components of Non-Small Cell Lung Cancers: A Repeatability Analysis in a Prospective Multicenter Cohort. J Nucl Med 2017; 58(3): 406–411. https://doi.org/10.2967/jnumed.116.180919 PMID: 27765856

47. Hatt M, Majdoub M, Vallieres M, et al. 18F-FDG PET uptake characterization through texture analysis: investigating the complementary nature of heterogeneity and functional tumour volume in a multi-cancer site patient cohort. J Nucl Med 2015; 56: 38–44. https://doi.org/10.2967/jnumed.114.144055 PMID: 25500829

48. Brooks FJ, Grigsby PW. The effect of small tumour volumes on studies of intratumoural heterogeneity of tracer uptake. J Nucl Med. 2014; 55: 37–42. https://doi.org/10.2967/jnumed.113.129858 PMID: 24549286

49. Orhtac F, Soussan M, Maissonobe J, et al. Tumour texture analysis in 18F-FDG PET: relationships between texture parameters, histogram indices, standardized uptake values, metabolic volumes, and total lesion glycolysis. J Nucl Med 2014; 55:414–422. https://doi.org/10.2967/jnumed.113.129858 PMID: 24549286

50. Chalkidou A, O’Doherty MJ, Marsden PK. False Discovery Rates in PET and CT Studies with Texture Features: A Systematic Review. PLoS One. 2015; 10(5): e0124165. https://doi.org/10.1371/journal.pone.0124165 PMID: 25900911

51. Walraven I, van den Heuvel M, van Diessen J, et al. Long-term follow-up of patients with locally advanced non-small cell lung cancer receiving concurrent hypofractionated chemoradiotherapy with or without cetuximab. Radiother Oncol 2016; 118:442–446. https://doi.org/10.1016/j.radonc.2016.02.011 PMID: 26900091

52. Detterbeck FC, Boffa JB, Kim AW, et al. The Eighth Edition Lung Cancer Stage Classification. CHEST 2017; 151(1):193–203. https://doi.org/10.1016/j.chest.2016.10.010 PMID: 27780786

53. Kruis MF, van de Kamer JB, Houweling AC, et al. PET motion compensation for radiation therapy using a CT-based mid-position motion model: methodology and clinical evaluation. Int J Radiat Oncol Biol Phys 2013; 87:394–400. https://doi.org/10.1016/j.ijrobp.2013.06.007 PMID: 23910710

54. van Griethuysen JJM, Fedorov A, Parmar C, et al. Computational Radiomics System to Decode the Radiographic Phenotype. Cancer Research 2017; 77(21):e104–e107. https://doi.org/10.1158/0008-5472.CAN-17-0338 PMID: 29092951

55. Haralick RM, Shanmugam K, Dinstein I. Textural features for image classification. IEEE Trans Syst Man Cybern 1973; 3:610–621.

56. Galloway MM. Texture analysis using gray level run lengths. Comput Graph Image Process 1975; 4:172–179.

57. Thibault G, Angulo J, Meyer F. Advanced statistical matrices for texture characterization: application to cell classification. IEEE Trans Biomed Eng 2014; 61:630–637. https://doi.org/10.1109/TBME.2013.2284600 PMID: 24106747

58. Sun CJ, Wee WG. Neighboring gray level dependence matrix for texture classification. Comput Vision Graph Image Process 1983; 23:341–52.

59. Amadasun M, King R. Textural features corresponding to textural properties. IEEE Trans Syst Man Cybern 1989; 19:1264–1274.
60. Zwanenburg A, Leger S, Vallières M, et al. Image biomarker standardisation initiative—feature definitions. 2016. In eprint arXiv:1612.07003.

61. Bland JM, Altman DG. Statistical Methods for Assessing Agreement between Two Methods of Clinical Measurement. Lancet 1986; 1(8476):307–10. PMID: 2868172

62. Shang J, Ling X, Zhang L, et al. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer. Eur J Nucl Med Mol Imaging 2016; 43:1945–53. https://doi.org/10.1007/s00259-016-3420-7 PMID: 27236466

63. Zambelli AE. A data-driven approach to estimating the number of clusters in hierarchical clustering. F1000Res 2016;

64. Friedman J, Hastie T, Tibshirani R. Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Soft 2010; 33(1):1–22.

65. Deist TM, Dankers FJWM, Valdes G, et al. Machine learning algorithms for outcome prediction in (chemo)radiotherapy: An empirical comparison of classifiers. Med Phys 2018; 45(7):3449–3459. https://doi.org/10.1002/mp.12967 PMID: 29763967

66. Zou H, Hastie T. Regularization and variable selection via the elastic net. J Royal Stat Soc B 2005; 67.

67. Larue RTHM, Van De Voorde L, van Timmeren JE, et al. 4DCT imaging to assess radiomics feature stability: an investigation for thoracic cancers. Radiother Oncol 2017; 125(1):147–153. https://doi.org/10.1016/j.radonc.2017.07.023 PMID: 28797700

68. Parmar C, Grossmann P, Bussink J, et al. Machine learning methods for quantitative radiomics biomarkers. Sci Rep. 2015; 5:13087. https://doi.org/10.1038/srep13087 PMID: 26278466

69. Konert T, van de Kamer JB, Sonke JJ, et al. The developing role of FDG PET imaging for prognostic application and radiotherapy target volume delineation in non-small cell lung cancer. J Thorac Dis 2018; 10 (21):2508–2521.

70. Lovinfosse P, Janvary ZL, Coucke P, et al. FDG PET/CT texture analysis for predicting the outcome of lung cancer treated by stereotactic body radiation therapy. Eur J Nucl Med Mol Imaging 2016; 43:1453–60. https://doi.org/10.1007/s00259-016-3314-8 PMID: 26830299

71. Takeda K, Takamami K, Shirata Y, et al. Clinical utility of texture analysis of 18F-FDG PET/CT in patients with Stage I lung cancer treated with stereotactic body radiotherapy. J Radiat Res 2017; 58 (6):862–869. https://doi.org/10.1093/jrr/rrx050 PMID: 29036692

72. Wu J, Aguilera T, Shultz D, et al. Early-Stage Non-Small Cell Lung Cancer: Quantitative Imaging Characteristics of (18)F Fluorodeoxyglucose PET/CT Allow Prediction of Distant Metastasis. Radiology 2016; 281(1):270–8. https://doi.org/10.1148/radiol.2016151829 PMID: 27046074

73. Yan J, Chu-Shern JL, Loi HY, et al. Impact of Image Reconstruction Settings on Texture Features in 18F–FDG PET. J Nucl Med 2015; 56(11):1667–73. https://doi.org/10.2967/jnumed.115.156927 PMID: 26229145

74. Orlhac F, Boughdad S, Philippe C, et al. A Postreconstruction Harmonization Method for Multicenter Radiomic Studies in PET. J Nucl Med. 2018 Aug; 59(8):1321 –1328. https://doi.org/10.2967/jnumed.117.199935 PMID: 29301932

75. Pavlou M, Ambler G, Seaman S, et al. Review and evaluation of penalised regression methods for risk prediction in low-dimensional data with few events. Stat Med 2015; 35:1159–1177. https://doi.org/10.1002/sim.6782 PMID: 26514699

76. Yip S, McCall K, Aristophanous M, et al. Comparison of texture features derived from static and respiratory-gated PET images in non-small cell lung cancer. PLoS One 2014; 9:e115510. https://doi.org/10.1371/journal.pone.0115510 PMID: 25517987

77. Yu K-H, Zhang C, Berry GJ, et al. Predicting non-small cell lung cancer prognosis by fully automated microscopic pathology image features. Nat. Commun. 2016; 7:12474. https://doi.org/10.1038/ncomms12474 PMID: 27527408

78. Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology 2016; 278:563–577. https://doi.org/10.1148/radiol.2015151169 PMID: 26579733

79. Parmar C, Leijenaar RT, Grossmann P, et al. Radiomic feature clusters and prognostic signatures specific for lung and head & neck cancer. Sci Rep 2015; 5:11044. https://doi.org/10.1038/srep11044 PMID: 26251068

80. Bertolaccini L, Solli P, Pardolesi A, et al. An overview of the use of artificial neural networks in lung cancer research. J Thorac Dis 2017; 9:924–931. https://doi.org/10.21037/jtd.2017.03.157 PMID: 28523139

81. Hosny A, Parmar C, Quackenbush J, et al. Artificial intelligence in radiology. Nat Rev Cancer. 2018 Aug; 18(8):500–510. https://doi.org/10.1038/s41568-018-0016-5 PMID: 29777175
82. Murphy A, Skalski M, Gaillard F. The utilisation of convolutional neural networks in detecting pulmonary nodules: a review. Br J Radiol 2018; 91(1090):20180028. https://doi.org/10.1259/bjr.20180028 PMID: 29869919

83. Vaidya M, Creach KM, Frye J, et al. Combined PET/CT image characteristics for radiotherapy tumour response in lung cancer. Radiother Oncol 2012; 102(2):239–45. https://doi.org/10.1016/j.radonc.2011.10.014 PMID: 22098794

84. Vallières M, Freeman CR, Skamene SR, et al. A radiomics model from joint FDG-PET and MRI texture features for the prediction of lung metastases in soft-tissue sarcomas of the extremities. Phys Med Biol 2015 Jul 21; 60(14):5471–96. https://doi.org/10.1088/0031-9155/60/14/5471 PMID: 26119045
Author/s:
Konert, T; Everitt, S; La Fontaine, MD; van de Kamer, JB; MacManus, MP; Vogel, WV; Callahan, J; Sonke, J-J

Title:
Robust, independent and relevant prognostic F-18-fluorodeoxyglucose positron emission tomography radiomics features in non-small cell lung cancer: Are there any?

Date:
2020-02-25

Citation:
Konert, T., Everitt, S., La Fontaine, M. D., van de Kamer, J. B., MacManus, M. P., Vogel, W. V., Callahan, J. & Sonke, J. -J. (2020). Robust, independent and relevant prognostic F-18-fluorodeoxyglucose positron emission tomography radiomics features in non-small cell lung cancer: Are there any?. PLOS ONE, 15 (2), https://doi.org/10.1371/journal.pone.0228793.

Persistent Link:
http://hdl.handle.net/11343/244192

File Description:
published version

License:
CC BY